Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viet Nam Pharmaceutical - JSCHSTC:DVN -2.01%80 Return-on-Tangible-Equity is 15.44% as of Mar. 2026, which is 87% above its 10-year median of 8.26. GuruFocus rates HSTC:DVN with a GF Score™ of 80/100 and a GF Value™ of ₫22,076.80 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 901 Drug Manufacturers companies, Viet Nam Pharmaceutical - JSC ranks better than 79.91% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Viet Nam Pharmaceutical - JSC's annualized net income for the quarter that ended in Mar. 2026 was ₫568,141 Mil. Viet Nam Pharmaceutical - JSC's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₫3,680,460 Mil. Therefore, Viet Nam Pharmaceutical - JSC's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 15.44%.
The historical rank and industry rank for Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Equity or its related term are showing as below:
HSTC:DVN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.28 Med: 8.26 Max: 21.95
Current: 20.45
During the past 7 years, Viet Nam Pharmaceutical - JSC's highest Return-on-Tangible-Equity was 21.95%. The lowest was 3.28%. And the median was 8.26%.
HSTC:DVN's Return-on-Tangible-Equity is ranked better than 79.91% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs HSTC:DVN: 20.45
Viet Nam Pharmaceutical - JSC (HSTC:DVN) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Viet Nam Pharmaceutical - JSC Return-on-Tangible-Equity Related Terms
Viet Nam Pharmaceutical - JSC Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viet Nam Pharmaceutical - JSC Return-on-Tangible-Equity Chart
HSTC:DVN vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viet Nam Pharmaceutical - JSC Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 15.44% mean?
Viet Nam Pharmaceutical - JSC (HSTC:DVN) has a Return-on-Tangible-Equity of 15.44% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Viet Nam Pharmaceutical - JSC and its competitors. This is 87% above median its historical median of 8.26. Over the past decade, Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Equity has ranged from 3.28 to 21.95. According to the industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #181 out of 901 companies in the Drug Manufacturers industry, placing it in the top 20.1%.
Is Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Equity too high?
Viet Nam Pharmaceutical - JSC's current Return-on-Tangible-Equity of 15.44% is 87% above median its 10-year median of 8.26. Over the past 10 years, this metric has ranged from a low of 3.28 to a high of 21.95. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Viet Nam Pharmaceutical - JSC's value of 15.44% is 95.4% above this industry median. Based on the distribution chart, Viet Nam Pharmaceutical - JSC ranks #181 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Viet Nam Pharmaceutical - JSC has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Viet Nam Pharmaceutical - JSC's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Viet Nam Pharmaceutical - JSC ranks #181 out of 901 companies for Return-on-Tangible-Equity. This places Viet Nam Pharmaceutical - JSC in the top 20% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Viet Nam Pharmaceutical - JSC's value of 15.44% is 95.4% above this benchmark. Historically, Viet Nam Pharmaceutical - JSC's own Return-on-Tangible-Equity has ranged from 3.28 to 21.95 over the past decade. While the company's 10-year median is 8.26 vs. the industry median of 7.90, Viet Nam Pharmaceutical - JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viet Nam Pharmaceutical - JSC's current Return-on-Tangible-Equity of 15.44% is 95.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Viet Nam Pharmaceutical - JSC and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viet Nam Pharmaceutical - JSC's current Return-on-Tangible-Equity is 15.44%, which is 87% above median its own 10-year median of 8.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viet Nam Pharmaceutical - JSC stock overvalued right now?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC (HSTC:DVN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫22,076.80, compared to a current price of ₫19,500.00 — trading 11.7% below its estimated fair value. The current Return-on-Tangible-Equity is 15.44%, which is 87% above median its 10-year median of 8.26 and 95.4% above the Drug Manufacturers industry median of 7.90. Viet Nam Pharmaceutical - JSC's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Viet Nam Pharmaceutical - JSC (HSTC:DVN), the current Return-on-Tangible-Equity is 15.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viet Nam Pharmaceutical - JSC (HSTC:DVN) Overvalued in 2026?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC stock appears to be undervalued.
The current stock price of ₫19,500.00 is trading 11.7% below its estimated GF Value™ of ₫22,076.80.
GuruFocus considers Viet Nam Pharmaceutical - JSC to be Modestly Undervalued.
Key valuation signals for HSTC:DVN:
Return-on-Tangible-Equity: 15.44% (87% above median its 10-year median of 8.26)
GF Value™: ₫22,076.80 vs. price of ₫19,500.00 (11.7% below fair value)
Industry Position: 95.4% above the Drug Manufacturers median (#181 of 901)
No single metric tells the full story. See the HSTC:DVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viet Nam Pharmaceutical - JSC Business Description
Viet Nam Pharmaceutical Corp - JSC is engaged in the manufacturing of drugs. The company provides testing services for drugs and medicinal ingredients.
80GF Score
Get the complete analysis for HSTC:DVN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:DVN has been successfully added to your 
